Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Bach

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 28, 2024
Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUSPaulus Kirchhof, Sylvia Haas, Pierre Amarenco, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 28, 2018
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUSA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Clinical Cardiology|September 8, 2020
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective studyA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Research and Practice in Thrombosis and Haemostasis|December 8, 2021
Cancer-Associated ThrOmboSIs - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - Baseline characteristics and clinical outcomesAnthony Maraveyas, Jan Beyer-Westendorf, Agnes Y Lee, et al.
Journal of the American College of Cardiology|July 7, 2018
Global Prospective Safety Analysis of RivaroxabanPaulus Kirchhof, Ghazi Radaideh, Young-Hoon Kim, et al.
Thrombosis Research|July 31, 2021
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO studyAlexander T Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, et al.
Thrombosis and Haemostasis|September 3, 2020
Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)Nils Picker, Agnes Y Lee, Alexander T Cohen, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 28, 2024
Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUSPaulus Kirchhof, Sylvia Haas, Pierre Amarenco, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 28, 2018
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUSA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Clinical Cardiology|September 8, 2020
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective studyA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Research and Practice in Thrombosis and Haemostasis|December 8, 2021
Cancer-Associated ThrOmboSIs - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - Baseline characteristics and clinical outcomesAnthony Maraveyas, Jan Beyer-Westendorf, Agnes Y Lee, et al.
Journal of the American College of Cardiology|July 7, 2018
Global Prospective Safety Analysis of RivaroxabanPaulus Kirchhof, Ghazi Radaideh, Young-Hoon Kim, et al.
Thrombosis Research|July 31, 2021
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO studyAlexander T Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, et al.
Thrombosis and Haemostasis|September 3, 2020
Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)Nils Picker, Agnes Y Lee, Alexander T Cohen, et al.
Pageof 2